Serotonin and the heart

References

• Frishrnan W H, Mosenkis A, Huberfeld S, Okin S. Serotonin and serotonin antagonism in cardiovascular disease. Cardiovascular phannacotherapeutics, W H Frishman, E H Sonnenblick. McGraw Hill, New York, NY, 639–75
   Google Scholar
• Hedner T, Persson B. Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension. Am J Hypertens 1988; 1: 317s–28s
   Google Scholar
• Houston D, Vanhoutte P. Serotonin and the vascular system: role in health and disease and implications for therapy. Drugs 1986; 31: 149–61
   PubMed Web of Science ®Google Scholar
• Page I H. Serotonin (5-hydroxytryptamine). Physiol Rev 1954; 14: 563–88
   Google Scholar
• Frishrnan W H, Okin S, Huberfeld S. Serotonin antagonism in the treatment of systemic hypertension: the role of ketanserin. Med Clin North Am 1988; 72: 501–22
   PubMedGoogle Scholar
• Myers J, Mecca T, Webb R. Direct and sensitizing effects of serotonin agonist and antagonists on vascular smooth muscle. J Cardiouusc Pharmacol 1985; 7(Suppl 7)S44–8
   Google Scholar
• Cohen R. Serotonin and the blood-vessel wall. J Hypertens 1986; 4(SUPPI 5)S116–8
   Google Scholar
• Friehrnan W H, Huberfeld S, Okin S, Wang Y H, Kurnar A, Shareef B. Serotonin and serotonin antagonism in cardiovascular and noncardiovascular disease. J Clin Pharmacol 1995; 35: 541–72
   PubMedGoogle Scholar
• Vanhoutte P, Luscher T. Serotonin and the blood vessel wall. J Hypertens 1986; 4(Suppl 1)S29–35
   Google Scholar
• Van Nueten J, Janssens W. Augmentation of vasoconstrictor responses to serotonin by acute and chronic factors: inhibition by ketanserin. J Hypertens 1986; 4(Suppl 1)S55–9
   Google Scholar
• Yildiz O, Smith J R, Pardy R E. Serotonin and vasoconstrictor synergism. Life Sci 1998; 62: 1723–32
   PubMed Web of Science ®Google Scholar
• Vanhoutte P. Serotonin and the blood vessel wall. J Hypertens 1986; 4(Suppl 5)S112–5
   Google Scholar
• Vikenes K, Farstad M, Nordrehaug J E. Serotonin is associated with coronary artery disease and cardiac events. Circulation 1999; 100: 483–9
   PubMed Web of Science ®Google Scholar
• Arinami T, Ohtsuki T, Yamakawa-Kobayashi K, Amemiya H, Fujiwara H, Kawata K, et al. A synergistic effect of serotonin transporter gene polymorphism and smoking in association with CHD. Thromb Haemost 1999; 81: 853–6
   PubMedGoogle Scholar
• Comings D E, MacMurray J P, Gonzalez N, Ferry L, Peters W R. Association of the serotonin transporter gene with serum cholesterol levels and heart disease. Mol Genet Metab 1999; 67: 248–53
   PubMed Web of Science ®Google Scholar
• Hollenberg N. Serotonin and the peripheral circulation. J Hypertens 1986; 4(Suppl 1)S23–7
   Google Scholar
• Janssen P. Pharmacology of potent and selective S2 seroton-ergic antagonists. J Cardiovasc Pbarmacol 1985; 7(Suppl 7)s2–11
   Google Scholar
• Wright L, Homans D, Laxson D, Dai X, Bache R J. Effects of serotonin and thromboxane A2 on blood flow through moderately well developed coronary artery vessels. J Am CON Curdiol 1992; 19: 687–93
   PubMed Web of Science ®Google Scholar
• Van Nueten J. Serotonin and the blood vessel wall. J Cardiovasc Pharmacol 1985; 7(Suppl 7)S49–51
   Google Scholar
• Tschudi M R, Luscher T F. Age and hypertension differently affect coronary contractions to endothelin-1, serotonin, and angiotensins. Circulation 1995; 91: 2415–22
   PubMed Web of Science ®Google Scholar
• Doggrell S A. Increase in affinity and loss of 5-hydroxy-tryptamine 2A-receptor reserve for 5-hydroxytryptamine on the aorta of spontaneously hypertensive rats. J Auton Pharmacol 1995; 15: 371–7
   PubMedGoogle Scholar
• Benzuly K H, Padgett R C, Kaul S, Piegors D J, Armstrong M L, Heistad D D. Functional improvement precedes structural regression of atherosclerosis. Circulation 1994; 89: 1810–8
   PubMedGoogle Scholar
• Heistad D D, Armstrong M L, Baumbach G L, Faraci F M. Sick vessel syndrome. Recovery of atherosclerotic and hypertensive vessels. Hypertension 1995; 26: 509–13
   PubMedGoogle Scholar
• Ustunes L, Yasa M, Kerry Z, Ozdemir N, Berkan T, Erhan Y, et al. Effect of verapamil on intimal thickening and vascular reactivity in the collared carotid artery of the rabbit. Br J Pharmucol 1996; 118: 1681–8
   PubMedGoogle Scholar
• Yokota Y, Imaizumi Y, Asano M, Matsuda T, Watanabe M. Endothelium-derived relaxing factor released by 5-HT: distinct from nitric oxide in basilar arteries of normotensive and hypertensive rats. Br J Pharmacol 1994; 113: 324–30
   PubMedGoogle Scholar
• Matsuda K, Lozinskaya I, Cox R H. Augmented contributions of voltage-gated Ca2+ channels to contractile responses in spontaneously hypertensive rat rnesenteric arteries. Am J Hypertens 1997; 10: 1231–9
   PubMedGoogle Scholar
• Bell D R. Effect of chronic high pressure on transient and tonic vascular contractions to serotonin in hypertension. Am J Hypertens 1995; 8(4 Pt 1)365–74
   PubMedGoogle Scholar
• Mandinov L, Kaufmann P, Maier W, Hess O M. Flow-dependent vasodilation in the coronary circulation: alterations in diseased states. Semin Znterv Curdiol 1998; 3: 5–12
   PubMedGoogle Scholar
• Vanhoutte P M. Endothelial dysfunction and vascular disease. Verb K Acud Geneeskd Belg 1998; 60: 251–66
   PubMedGoogle Scholar
• Vanhoutte P M. Endothelial dysfunction and atherosclerosis. Eur Heart J 1997; 18(Suppl E)E19–29
   Google Scholar
• Shimada T, Murakami Y, Hashimoto M, Ishibashi Y, Inoue S, Katoh H, et al. Impairment of serotonin-mediated nitric oxide release across the coronary bed in patients with coronary spastic angina. Am J Cardiol 1999; 83: 953–5
   PubMedGoogle Scholar
• Murakami Y, Shimada T, Ishinaga Y, Kmoshita Y, Kin H, Kitarnura J, et al. Transcardiac 5-hydroxytryptamine release and impaired coronary endothelial function in patients with vasospastic angina. Clin Exp Pharrnacol Physiol 1998; 25: 999–1003
   PubMedGoogle Scholar
• Murakami Y, Ishinaga Y, Sano K, Murakami R, Kinoshita Y, Kitamura J, et al. Increased serotonin release across the coronary bed during a nonischemic interval in patients with vasospastic angina. Clin Cardiol 1996; 19: 473–6
   PubMed Web of Science ®Google Scholar
• Takeshita A. Endothelin-1 is not involved in serotonin-induced coronary spasm in a swine model. Cardiovasc Res 1995; 30: 193–9
   PubMedGoogle Scholar
• Stassen F R, Fazzi G E, Leenders P J, Smits J F, De Mey J G. Coronary arterial hyperreactivity and mesenteric arterial hyporeactivity after myocardial infarction in the rat. J Cardiovasc Pbarmacol 1997; 29: 780–8
   PubMedGoogle Scholar
• Mongiardo R, Finocchiaro M L, Beltrame J, Pristipino C, Lombardo A, Cianflone D, et al. Low incidence of serotonin-induced occlusive coronary artery spasm in patients with recent myocardial infarction. Am J Cardiol 1996; 78: 84–7
   PubMedGoogle Scholar
• Meyrelles S S, Bernardes C F, Modolo R P, Mill J G, Vasquez E C. Bezold-Jarisch reflex in myocardial infarcted rats. J Auton New Syst 1997; 63: 144–52
   PubMedGoogle Scholar
• Breuer J, Meschig R, Breuer H, Arnold G. Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin. J Cardiovasc Pharmacol 1985; 7(Suppl 7)S64–6
   Google Scholar
• Missouris C G, Cappucio F P, Varsamis E, Barron J L, Carr E, Markandu N D, et al. Serotonin and heart rate in hypertensive and normotensive subjects. Am Heart J 1998; 135: 838–43
   PubMedGoogle Scholar
• Belougne-Malfatti E, Aguejouf O, Doutremepuich F, Doutremepuich C. Actions of neurotransmitters: acetyl-choline, serotonin, and adrenaline in an experimental arterial thrombosis induced by oxygen free radicals. Thromb Res 1997; 88: 435–9
   PubMedGoogle Scholar
• Takano S. Role of 5-hydroxytryptamine in platelet thrombus formation and mechanisms of inhibition of thrombus formation by 5-hydroxytryptamine2A antagonists in rabbits. Arch lnt Pharmacodyn Ther 1995; 330: 297–308
   PubMedGoogle Scholar
• De Cree J, Leempoels J, De Cock W, Geukens H, Verhaegen H. The antihypertensive effects of a pure and selective serotonin receptor blocking agent (R 41 468) in elderly patients. Angiology 1982; 32: 132–44
   Google Scholar
• Baudouin-Legros M, Le Quan-Bui K, Guicheney P, Kamal L, Meyer P. Platelet serotonin in essential hypertension and in mental depression. J Cardiovasc Pharmacol 1985; 7(Suppl 7)s12–4
   PubMedGoogle Scholar
• Mantero F, Rocco S, Opocher G, Armanini D, Boscaro M, D'Agostino D. Effect of ketanserin in primary aldosteronism. J Cardiovasc Pharmacol 1985; 7(Suppl 7)S172–5
   Google Scholar
• Chalmers J P, Pilowsky P M, Minson J B, Kapoor V, Mills E, West M J. Central serotonergic mechanisms in hypertension. Am J Hypertens 1988; 1: 79–83
   PubMedGoogle Scholar
• Serotonin and the cardiovascular system, P Vanhoutte. Raven Press, New York, NY 1985
   Google Scholar
• McCall R B, Clement M E. Role of serotonin lA and serotonin2 receptors in the central regulation of the cardiovascular system. Pharmacol Rev 1994; 46: 231–43
   PubMed Web of Science ®Google Scholar
• Chaouche-Teyara K, Lacolley P, Challande P, Fournier B, Laurent S, Safar M, et al. Effects of clonidine and flesinoxan on blood pressure variability in conscious spontaneously hypertensive rats. J Cardiovasc Pbarmacol 1997; 30: 241–4
   PubMedGoogle Scholar
• Hansson L, Petitet A. Review of studies with urapidil in elderly hypertensives. Blood Press 1995, Suppl 3: 21–5
   Google Scholar
• Lee J Y, Hancock A A, Warner R B, Brune M E, Meyer M D, DeBernardis J F. Cardiovascular activity of A-74283, a 5-hydroxytryptamine 1A agent, in the spontaneously hypertensive rat. Pharmacology 1998; 56: 17–29
   PubMedGoogle Scholar
• Anderson M, Martin G R, Ramage A G. Evidence that activation of 5-HT2 receptors in the forebrain of anaesthetized cats causes sympathoexcitation. Br J Pharmacol 1995; 116: 1751–6
   PubMedGoogle Scholar
• Yoshioka M. Effect of a novel 5-hydroxytryptamine3-antagonist, CR38032F, on the 5-hydroxytryptamine-induced increase in carotid sinus nerve activity in rats. J Pharmacol Exp Ther 1989; 250: 637–41
   PubMedGoogle Scholar
• Pilowsky P M, Minson J B, Arnolda L F, Chalmers J P. Brain serotonin and hypertension. Hypertension: pathophysiology, diagnosis, and management. 2nd edn., J H Laragh, B M Brenner. Raven Press, New York, NY 1995; 775–87
   Google Scholar
• Veelken R, Sawin L L, DiBona G F. Epicardial serotonin receptors in circulatory control in conscious Spague-Dawley rats. Am J Physiol 1990; 258: H466–72
   Google Scholar
• Fagard R, Fiocchi R, Lijnen P, Staessen J, Moerman E, Schaepdryver A, et al. Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J 1984; 51: 149–56
   PubMedGoogle Scholar
• Gradin K, Pettersson A, Hedner T, Persson B. Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat. J Neural Trans 1985; 64: 145–9
   PubMedGoogle Scholar
• Ameklo-Nobin B, Nobin A, Owman C, Tornebrandt K. Serotonergic mechanism in isolated human peripheral arteries and veins. J Cardiovasc Pharmacol 1985; 7(Suppl 7)S52–5
   Google Scholar
• deLeeuw P, Birkenhager W. Chronic effects of serotonin inhibition in hypertensive patients: hemodynamic and humoral findings. J Cardiovasc Pharmacol 1985; 7(Suppl 7)S137–9
   Google Scholar
• Reimann I, Frolich J. Mechanism of antihypertensive action of ketanserin in man. BMJ 1983; 287: 381–3
   PubMed Web of Science ®Google Scholar
• Wenting G, Woittiez A, Man Int'Veld A, Schalekamp A. 5-HT, alpha-adrenoreceptors, and blood pressure effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension 1984; 6: 100–9
   PubMed Web of Science ®Google Scholar
• Hara H, Kitajima A, Shimada H, Tamao Y. Antithrombotic effect of MC1-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemostas 1991; 66: 484–8
   PubMed Web of Science ®Google Scholar
• Herbert J M, Bernat A, Barthelemy G, Dol F, Rinaldi M. Anti-thrombotic activity of SR 46349, a novel, potent and 80. selective 5-HT2 receptor antagonist. Thromb Haemostas 1993; 69(3)262–7
   PubMedGoogle Scholar
• Wilson H C, Coffman W, Killam A, Cohen M L. LY53857, a 5-HT2 receptor antagonist, delays occlusion and inhibits platelet aggregation in a rabbit model of carotid artery occlusion. Thromb Haemostas 1991; 66: 355–60
   PubMedGoogle Scholar
• Fagard R, Fiocchi R, Lijnen P, Staessen J, Amery A. Hemodynamic response to chronic ketanserin treatment in essential hypertension. J Cardiouasc Pharmacol 1985; 7(Suppl 7)S128–9
   Google Scholar
• Gradin K, Pettersson A, Hedner T, Persson B. Antihypertensive effects of ketanserin in the spontaneously hypertensive rat: mode of action. J Cardiovasc Pharmacol 1985; 7(Suppl 7)S110–11
   Google Scholar
• Gasic S, Eichler H, Korn A. Effect of ketanserin on phenyl-ephrine-dependent changes in splanchnic hemodynamics and systemic blood pressure in healthy subjects. J Cardiovasc Phamacol 1985; 7: 219–23
   PubMedGoogle Scholar
• BalaSubramanian H, Lee S, Mah S C. Differences in the acute and chronic antihypertensive mechanism of action of ketanserin in spontaneously hypertensive rats. J Pharmacol Exp Ther 1993; 264: 129–34
   PubMedGoogle Scholar
• Lauw G, van Brummelem P, Doorenbos C, van der Velde E, van Zwieten P. The acute and chronic antihypertensive effects of ketanserin cannot be explained by blockade of vascular serotonin type 2, receptor or (1-adrenergic receptors. Clin Pharmacol Ther 1991; 49: 377–84
   PubMedGoogle Scholar
• Nelson M, Coghlan J, Denton D, Mills E, Scoggins B, Spence C, et al. Serotonergic mechanisms and blood pressure in sheep. J Cardiovasc Pharmacol 1985; 7(Suppl 7)S117–9
   Google Scholar
• Furukawa Y, Saegusa K, Ogiwara Y, Chiba S. Effects of ketanserin on the pacemaker activity and contractility in the isolated, blood perfused dog atrium. J Curdiouasc Pharmacol 1986; 8: 967–72
   PubMedGoogle Scholar
• Fernández M, Pizcueta P, Garcia-Pagan J C, Feu F, Cirera I, Bosch J, et al. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. Hepatology 1993; 18: 389–93
   PubMedGoogle Scholar
• Hosie J, Stott D J, Robertson J IS, Ball S G. Does acute serotonergic type 2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension. J Cardiovasc Pharmacol 1987; 10(SUPPI 3)S86–8
   Google Scholar
• Naslund T C, Merrell W J, Nadeau J H, Wood A JJ. α-adrenergic blockade makes minimal contribution to ketanserin's hypotensive effect. Clin Pharmacol Ther 1988; 44: 699–703
   PubMedGoogle Scholar
• McCall R B, Harris L T. Characterization of the central sympatho-inhibitory action of ketanserin. J Pharm Exp Ther 1987; 241: 736–40
   PubMedGoogle Scholar
• Reimann I, Ziegler G, Ludwig L, Frolich J. Central and autonomic nervous system side effects of ketanserin. Arzneimittelforschung 1986; 36(II)1681–4
   PubMedGoogle Scholar
• van Zwieten P A, Mathy M J, Boddeke H WGM, Doods H N. Central hypertensive activity of ketanserin in cats. J Cardiovasc Pharmacol 1987; 10(Suppl 3)S54–8
   Google Scholar
• Hoyer D, Vos P, Closse A, Palacios J M, Engel G, Davies H. [3H] ketanserin labels 5-HT2 and alpha 1-receptors in human brain cortex. J Cardiovasc Pharmacol 1987; 10(Suppl 3)S48–50
   Google Scholar
• Berdeaux A, Edourad A, Samii K, Giudicelli J F. Ketanserin and the baroreceptor reflex in normotensive individuals. Eur J Clin Pharmacol 1987; 32: 27–33
   PubMedGoogle Scholar
• Wenting G, Man Int'Veld A, Woittiez A, Boomsma F, Schalekamp M. Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. BMJ 1982; 284: 537–9
   PubMed Web of Science ®Google Scholar
• Breckenridge A. Ketanserin — a new antihypertensive agent. J Hypertens 1986; 4(Suppl 1)S13–6
   PubMedGoogle Scholar
• Ferrara L, Fasano M, Soro S, Rubba P, Iannuzzi A. Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension. J Clin Phamacol 1985; 25: 187–92
   Google Scholar
• Ichikawa Y, Yokoyama M, Akita H, Fukuzaki H. Constriction of a large coronary artery contributes to serotonin induced myocardial ischemia in the dog with pliable coronary stenosis. J Am Coll Cardiol 1989; 14(2)449–59
   PubMedGoogle Scholar
• Hedner T, Persson B. Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension. Br J CIin Pharmacol 1984; 18: 765–71
   PubMedGoogle Scholar
• Cameron H, Ramsay L. Ketanserin in essential hypertension: a double-blind, placebo-controlled study. Postgrad Med J 1985; 61: 583–86
   PubMedGoogle Scholar
• Navis G, deJong P, van der Hem G, deZeeuw D. Renal effects of ketanserin in essential hypertension. J Hypertens 1986; 4(Suppl 1)S95–8
   Google Scholar
• Amery A, Fagard R, Fiocchi R, Lijnen P, Staessen J, Vermylen J. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients. J Cardiovasc Pharmacol 1984; 6: 182–5
   PubMed Web of Science ®Google Scholar
• Persson B, Hedner T, Berglund G. Ketanserin in essential hypertension: effects during rest and exercise. Eur J Clin Phamacol 1983; 25: 307–12
   PubMed Web of Science ®Google Scholar
• Zehender M, Meinertz T, Hohnloser S, Geibel A, Hartung J, Seiler K -U, et al. Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Am J Cardiol 1989; 63: 826–32
   PubMed Web of Science ®Google Scholar
• Zehender M, Meinertz T, Hohnloser S, Geibel A, Hartung J, Seiler K -U, et al. Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Clin Physiol Biochem 1990; 8(Suppl 3)90–100
   PubMedGoogle Scholar
• Schalekamp A, Woittiez A, Wenting G, van den Meiracker A, Man Int'Veld A. Ketanserin: haemodynamic effects and mechanism of action. J Hypertens 1986; 4(Suppl 1)S7–12
   Google Scholar
• De Cree J, Leempoels J, Demoen B, Verhaegen H. Ketanserin and red blood cell sodium content in hypertension. J Curdiovasc Pharmacol 1985; 7(Suppl 7)S41–3
   Google Scholar
• Radermacher P, Huet Y, Pluskwa F, Herigault R, Mal H, Teisseire B, et al. Comparison of ketanserin and sodium nitroprusside in patients with severe ARDS. Anesthesiology 1988; 68: 152–7
   PubMed Web of Science ®Google Scholar
• Saman S, Thandroyen F, Opie L. Serotonin and the heart: effects of ketanserin on myocardial function, heart rate, and arrhythmias. J Curdiovasc Pharmacol 1985; 7(Suppl 7)S70–5
   Google Scholar
• Furukawa Y, Saegusa K, Ogiwara Y, Chiba S. Effects of ketanserin on the pacemaker activity and contractility in the isolated, blood perfused dog atrium. J Cardiovusc Pharmucol 1986; 8: 967–72
   PubMedGoogle Scholar
• Grobecker H, Gessler I, Delius W, Dominiak P, Kees F. Effect of ketanserin on hemodynamics, plasma catecholamine concentrations and serotonin uptake by platelets in volunteers and patients with congestive heart failure. J Curdiovasc Phurm 1985; 7(Suppl 7)S102–4
   PubMedGoogle Scholar
• Kamiya K, Venkatesh N, Sigh B. Acute and chronic effects of ketanserin on the electrophysiologic properties of isolated rabbit ventricular myocardium: particular reference to repolarization. Am Heart J 1988; 115: 1222–8
   PubMedGoogle Scholar
• Zaza A, Malfatto G, Rosen M R. Electrophysiologic effects of ketanserin on canine Purkinje fibers, ventricular myocardium and the intact heart. J Pharm Exp Ther 1989; 250: 397–405
   PubMedGoogle Scholar
• Cameron H A, Waller P C, Ramsay L E. The effect of ketanserin on the QT interval. Br J CIin Pharmacol 1987; 23: 630P
   Google Scholar
• Nademanee K, Lockhart E, Pruitt C, Singh B N. Cardiac electro-physiologic effects of intravenous ketanserin in humans. J Curdiovusc Phurmacol 1987; 10(Suppl 3)S81–5
   Google Scholar
• Prevention of Atherosclerotic Complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. BMJ 1989; 298: 424–30
   PubMed Web of Science ®Google Scholar
• Zannad F, Voisin P, Pointel J, Schmitt C, Freitag B, Stoltz J. Effects of ketanserin on platelet function and red cell filterability in hypertension and peripheral vascular disease. J Cardiovusc Pharmacol 1985; 7(Suppl 7)S32–4
   Google Scholar
• Waal-Manning H, Brown S, Spears G, Simpson G. Clinical studies with ketanserin in hypertension. J Cardiovasc Pharmacol 1985; 7(Suppl 7)S154–8
   Google Scholar
• De Clerck F, Jageneau A, Dom J. Hemorheological effects of ketanserin, a selective 5HT2-receptor antagonist, in aged, spontaneously hypertensive dogs. Arch Int Pharmacodyn 1982; 258: 100–15
   PubMedGoogle Scholar
• Kirch W, Ohnhaus E. Double-blind comparison of ketanserin with atenolol: antihypertensive activity and effect on platelet function. J Hypertens 1986; 4(Suppl 1)S67–71
   Google Scholar
• Arnout J, Van Russelt M, Deckmyn H, Vermylen J, Fiocchi R, Lijnen P, et al. Platelet hypersensitivity to serotonin after prolonged ketanserin intake. J Cardiovasc Pharmacol 1985; 7(Suppl 7)s20–2
   Google Scholar
• Gleerup G, Persson B, Hedner T, Winther K. Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists. Eur J Clin Pharmacol 1993; 44: 121–5
   PubMedGoogle Scholar
• Hedner T, Persson B, Berglund G. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension. Br J CIin Pharmucol 1983; 16: 121–5
   PubMed Web of Science ®Google Scholar
• Ferrara L, Fasano M, Soro S. Metabolic aspects of antihypertensive treatment with ketanserin (letter). J Cardiovasc Phurmacol 1985; 7: 1007–8
   PubMedGoogle Scholar
• DeMartini A, Pezano R, Bernardier E, Torres J, Genta C, Scheijgrond H, et al. Multicenter study with ketanserin in essential hypertension: an Argentine experiment. J Cardiovusc Pharmacol 1987; 10(Suppl 3)S125–37
   Google Scholar
• Ferrara L, Fasano M, Rubba P, Soro S, Marotta G, Mancini M. Study with the competitive 5-HT2 serotonergic antagonist ketanserin. J Cardiovusc Pharmucol 1985; 7(Suppl 7)S159–60
   Google Scholar
• Zabludowski J, Zoccali C, Isles C, Murray G, Robertson J, Inglis G, et al. Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in patients with essential hypertension. Br J Clin Pharmacol 1984; 17: 309–16
   PubMedGoogle Scholar
• Wing L, Chalmers J, West M, Bune A, Ayres B, Graham J. Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension. J Cardiovasc Pharmacol 1985; 7(Suppl 7)S1 64–7
   Google Scholar
• Sheps S, Schirger A, Zachariah P, Fisher L, Spiekerman R, Araas F, et al. Comparison of ketanserin and metoprolol in the treatment of essential hypertension. Arch Intern Med 1987; 147: 291–6
   PubMedGoogle Scholar
• Hedner T, Persson B, Berglund G. A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension. J Cardiovusc Pharmacol 1985; 7(Suppl 7)S148–53
   Google Scholar
• Doyle A E. Age-related effects of 5HT2 antagonists. J Cardiovasc Phurmacol 1991; 17(Suppl 5)S29–34
   Google Scholar
• McCokack P ME, Cox J P, Marron J, Mee F, Atkias N, O'Brien E, et al. The anti-hypertensive efficacy of ketanserin in the elderly evaluated by ambulatory blood pressure measurement. J Hum Hypertens 1990; 4: 565–70
   PubMedGoogle Scholar
• Could S E, Silas J H, Hosie J. Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?. Cardiovasc Drugs Ther 1990; 4: 88–92
   Google Scholar
• Staessen J, Fagard R, Riocchi R, Lijnen P, Rorive G, Amery A. Double-blind comparison of ketanserin with propranolol in hypertensive patients: interim report. J Cardiovusc Pharmacol 1985; 7(SUPPI 7)S140–7
   Google Scholar
• Malatino L S, Stancanelli B, Greco G, Polizzi G, Assogna G, Zanna C, et al. Comparison of ketanserin and enalapril in the treatment of mild to moderate essential hypertension. Cardiovasc Drug Ther 1990; 4: 123–6
   PubMedGoogle Scholar
• Hannedouche T, FiIlastre J P, Mimran A, deTreglode D, Schardt F, Rosenthal T, et al. Ketanserin versus nifedipine in the treatment of essential hypertension in patients over 50 years old: an international multicenter trial. J Cardiovusc Pharmacol 1987; 10(Suppl 3)S107–12
   PubMedGoogle Scholar
• Zin C, Copertari P, Landi E, San Martin C, Lopes M, Feruglio F, et al. Evaluation of a new antihypertensive agent ketanserin versus methyldopa in the treatment of essential hypertension in older patients: an international multicenter trial. J Cardiovusc Phurmacol 1987; 10(Suppl 3)S113–8
   PubMedGoogle Scholar
• Palermo A, Mara G, Pizza N, Constantini C, del Rosso G, Assogna G, et al. Clinical experience with ketanserin in the treatment of hypertension. J Hypertens 1986; 4(Suppl 1)S81–3
   Google Scholar
• Andren L, Svensson A, Dahlof B, Eggertsen R, Hansson L. Ketanserin in hypertension: early clinical evaluation and dose-finding study of a new 5HT2 receptor antagonist. Acta Med Scand 1983; 214: 125–30
   PubMed Web of Science ®Google Scholar
• Singh N K, Goyal R K. New classes of antihypertensive drugs: therapeutic potentials. CZin Exp Hypertens 1999; 21: 137–43
   PubMed Web of Science ®Google Scholar
• Watts S W. The development of enhanced arterial serotonergic hyperresponsiveness in mineralocorticoid hypertension. J Hypertens 1998; 16: 811–22
   PubMedGoogle Scholar
• Watts S W, Baez M, Webb R C. The 5-hydroxytryptamine2B receptor and 5-HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate-salt hypertensive rats. J Pharmacol Exp Ther 1996; 277: 1103–13
   PubMedGoogle Scholar
• Watts S W, Fink G D. 5-HTZB receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. Am J Physiol 1999; 276(3 Pt 2)H944–52
   Google Scholar
• Steyn D W, Odendaal H J. Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. Lancet 1997; 350: 1267–71
   PubMed Web of Science ®Google Scholar
• Okin S, Huberfeld S I, Frishman W H, Soberman J, Laifer L, Greenberg S, et al. Serotonergic blockade compared to beta-adrenergic blockade in systemic hypertension: a double-blind comparison of ketanserin to propranolol. J Clin Pharmacol 1988; 28: 1008–16
   PubMedGoogle Scholar
• Rosenthal J, Koehle W, Gruebel B, Fisher R. Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha blocker. J Hypertens 1986; 4(Suppl 1)S85–7
   PubMedGoogle Scholar
• Varga G, Kordas K, Burghardt B, Gacsalyi I, Szenasi G. Effect of deramciclane, a new 5-HT receptor antagonist, on cholecystokinin-induced changes in rat gastrointestinal function. Eur J Pharmacol 1999; 367: 315–23
   PubMedGoogle Scholar
• Kiendaum P, Braun M, Hohlfeld R, Weber A A, Sarbia M, Schror K. Antiatherosclerotic effects of oral naftidrofuryl in cholesterol-fed rabbits involve inhibition of neutrophil function. J Cardiovasc Pharmacol 1995; 25: 774–81
   PubMedGoogle Scholar
• Pakala R, Pakala R, Sheng W L, Benedict C R. Serotonin fails to induce proliferation of endothelial cells preloaded with eicosapentaenoic acid and docosahexaneoic acid. Atherosclerosis 1999; 145: 137–46
   PubMedGoogle Scholar
• Pakala R, Pakala R, Radcliffe J D, Benedict C R. Serotonininduced endothelial cell proliferation is blocked by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 115–23
   PubMed Web of Science ®Google Scholar